HIV Treatment Breakthrough Could Transform Care with Twice-Yearly Dosing
London, 25 February 2026
ViiV Healthcare’s groundbreaking research reveals potential twice-yearly HIV treatments that maintain viral suppression for up to seven months with a single injection. The investigational therapies, VH184 and lotivibart, demonstrate superior resistance profiles against drug-resistant HIV strains whilst requiring significantly fewer doses than current treatments. This advancement could revolutionise HIV care globally, particularly benefiting refugee populations where treatment adherence remains challenging and drug resistance concerns persist in humanitarian healthcare programmes.
Revolutionary Long-Acting Formulations Show Promise
The pharmaceutical breakthrough centres on VH184, a third-generation integrase strand transfer inhibitor (INSTI) that demonstrated remarkable durability in phase 1 trials [1]. Data presented on 25 February 2026 at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado, revealed that a single injection of VH184 maintained therapeutic drug levels for up to six months [1]. This represents a significant advancement over current HIV treatments, which typically require daily oral medication or monthly injections [GPT]. The investigational therapy’s enhanced resistance profile against bictegravir, a widely-used current treatment, suggests it could effectively combat drug-resistant HIV strains that pose particular challenges in resource-limited settings [1].
Clinical Trial Results Demonstrate High Efficacy Rates
Concurrent research on lotivibart (N6LS), a broadly neutralising antibody, has yielded equally promising results in the phase IIb EMBRACE study [2]. After 12 months of treatment, 94 per cent of participants receiving intravenous lotivibart maintained viral suppression when the drug was administered every four months in combination with monthly long-acting cabotegravir [2]. The subcutaneous formulation showed slightly lower but still substantial efficacy, with 82 per cent of participants maintaining viral suppression [2]. These results compare favourably to the 88 per cent viral suppression rate observed in the standard of care control group [2]. Notably, adverse events were significantly less frequent in the intravenous group at 24 per cent compared to 53 per cent in the subcutaneous group [2].
Enhanced Safety Profile and Patient Acceptance
The safety data reveals important considerations for clinical implementation, particularly regarding injection site reactions [2]. Higher grade infusion-site reactions (grade 3-4) occurred in 16 per cent of participants receiving subcutaneous lotivibart, whilst no such reactions were reported in the intravenous group [2][4]. Despite these differences, patient perception scores remained consistently positive throughout the study period, with injection acceptability ratings staying within the ‘very acceptable’ to ‘totally acceptable’ range [2][4]. The confirmed virologic failure rates remained low across all treatment groups, with 4 per cent failure in the intravenous group, 6 per cent in the subcutaneous group, and 4 per cent in the standard care group [4].
Implications for Global HIV Treatment Access
These developments arrive at a critical juncture for global HIV treatment programmes, particularly those serving refugee populations in East Africa where medication adherence and drug resistance present ongoing challenges [GPT]. Dr Kimberly Smith, Head of Research & Development at ViiV Healthcare, emphasised the transformative potential of these therapies, stating that the research efforts focus on ‘delivering best-in-class, long-acting therapies that challenge the status quo and help make HIV treatment a smaller, less frequent part of people’s lives’ [1]. The company plans to advance both treatments toward twice-yearly dosing regimens, with lotivibart studies already progressing to evaluate this ultra long-acting interval [2][4]. ViiV Healthcare, established in November 2009 as a collaboration between GSK and Pfizer, with Shionogi joining as a shareholder in October 2012, continues to undergo ownership restructuring following a 20 January 2026 agreement for Shionogi to replace Pfizer’s economic interest [1][2][4].